Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on December 15, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.
Cash runway is approximately 35 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 12 concluded trials, 92% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| October 20, 2027 | A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks | Trial Milestone | Phase 3 |
Track PHAT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open PHAT in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.